These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19601814)

  • 21. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL; Calabresi PA
    Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
    Vidal-Jordana A; Montalban X
    Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MS treatment: new perspectives.
    Comi G; Martino G
    Clin Neurol Neurosurg; 2006 Mar; 108(3):339-45. PubMed ID: 16386359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
    Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
    Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapies for multiple sclerosis : review and update].
    Havla J; Kümpfel T; Hohlfeld R
    Internist (Berl); 2015 Apr; 56(4):432-45. PubMed ID: 25720530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-Modifying Treatment in Progressive Multiple Sclerosis.
    Ciotti JR; Cross AH
    Curr Treat Options Neurol; 2018 Apr; 20(5):12. PubMed ID: 29627873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolution of inflammation during multiple sclerosis.
    Ruiz F; Vigne S; Pot C
    Semin Immunopathol; 2019 Nov; 41(6):711-726. PubMed ID: 31732775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?
    Hoffmann O; Gold R; Meuth SG; Linker RA; Skripuletz T; Wiendl H; Wattjes MP
    Ther Adv Neurol Disord; 2024; 17():17562864241229325. PubMed ID: 38332854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary Progressive Multiple Sclerosis: Definition and Measurement.
    Plantone D; De Angelis F; Doshi A; Chataway J
    CNS Drugs; 2016 Jun; 30(6):517-26. PubMed ID: 27166830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.
    Gakis G; Angelopoulos I; Panagoulias I; Mouzaki A
    Autoimmun Rev; 2024 Feb; 23(2):103480. PubMed ID: 38008300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly active multiple sclerosis: An update.
    Díaz C; Zarco LA; Rivera DM
    Mult Scler Relat Disord; 2019 May; 30():215-224. PubMed ID: 30822617
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.